Literature DB >> 19415734

Heparin induced thrombocytopenia and re-thrombosis associated with warfarin and fondaparinux in a child.

Scott H Maurer1, Judith A Wilimas, Winfred C Wang, Ulrike M Reiss.   

Abstract

An 11-year-old female developed heparin induced thrombocytopenia (HIT) with thrombosis during therapy for lower extremity deep vein thrombosis and pulmonary embolism. Transition from bivalirudin, a direct thrombin inhibitor (DTI), to warfarin resulted in extensive re-thrombosis, and fondaparinux therapy similarly failed. She was then treated with argatroban, and transitioned successfully to warfarin after 9 weeks. The risk of re-thrombosis was ultimately reduced by allowing time for the thrombogenic potential to abate. The argatroban/warfarin transition was monitored with chromogenic factor X levels. This case highlights several difficult problems in pediatric thrombosis. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415734      PMCID: PMC4778081          DOI: 10.1002/pbc.22067

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  20 in total

1.  Heparin-induced thrombocytopenia associated with fondaparinux.

Authors:  Theodore E Warkentin; Brian T Maurer; Richard H Aster
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

Review 2.  Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update.

Authors:  Andreas Greinacher; Theodore E Warkentin
Journal:  Thromb Res       Date:  2005-09-01       Impact factor: 3.944

3.  Coagulation laboratory testing in patients treated with argatroban.

Authors:  J M Walenga; A R Fasanella; O Iqbal; D A Hoppensteadt; S Ahmad; D E Wallis; M Bakhos
Journal:  Semin Thromb Hemost       Date:  1999       Impact factor: 4.180

4.  Multicenter evaluation of a new chromogenic factor X assay in plasma of patients on oral anticoagulants.

Authors:  N Ciavarella; S Coccheri; G F Gensini; H J Hassan; P M Mannucci; C Manotti; E Margstakler; G Mariani; M Orlando; G Palareti; M Petronelli; E Pogliani; O Ponari; D Prisco; P Recalcati; E Rossi; C Salvitti; A Tripodi
Journal:  Thromb Res       Date:  1980 Aug 15-Sep 1       Impact factor: 3.944

5.  Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin.

Authors:  Paul A Arpino; Zareh Demirjian; Elizabeth M Van Cott
Journal:  Pharmacotherapy       Date:  2005-02       Impact factor: 4.705

Review 6.  Heparin-induced thrombocytopenia: treatment options and special considerations.

Authors:  William E Dager; John A Dougherty; Phuong H Nguyen; Michael A Militello; Maureen A Smythe
Journal:  Pharmacotherapy       Date:  2007-04       Impact factor: 4.705

7.  Bivalirudin for anticoagulation in children.

Authors:  Sobharani Rayapudi; Adalberto Torres; Girish G Deshpande; Mitchell P Ross; Julie D Wohrley; Guy Young; Michael D Tarantino
Journal:  Pediatr Blood Cancer       Date:  2008-12       Impact factor: 3.167

8.  Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Theodore E Warkentin; Andreas Greinacher; Andreas Koster; A Michael Lincoff
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis.

Authors:  G Young; M D Tarantino; J Wohrley; L C Weber; M Belvedere; D J Nugent
Journal:  J Thromb Haemost       Date:  2007-08       Impact factor: 5.824

Review 10.  The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update.

Authors:  Margaret Prechel; Jeanine M Walenga
Journal:  Semin Thromb Hemost       Date:  2008-02       Impact factor: 4.180

View more
  4 in total

1.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Successful use of fondaparinux in a patient with a mechanical heart valve replacement and a history of heparin-induced thrombocytopenia.

Authors:  Tia L Corbett; Kathy S Elher; Candice L Garwood
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

3.  Fondaparinux in an obese child with heparin-induced thrombocytopenia and a history of renal failure.

Authors:  Peter N Johnson; Emily C Benefield; Phi-Yen N Bui; Richard A Marlar; Morris R Gessouroun
Journal:  J Pediatr Pharmacol Ther       Date:  2013-10

4.  Heparin-induced thrombocytopenia in the pediatric population: a review of current literature.

Authors:  Niyati H Vakil; Abir O Kanaan; Jennifer L Donovan
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.